Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zonampanel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 known ✓ | P42261 | 5/20 | 0.76 |
| ▸ | GRIA2 known ✓ | P42262 | 5/20 | 0.76 |
| ▸ | GRIA3 known ✓ | P42263 | 5/20 | 0.76 |
| ▸ | GRIA4 known ✓ | P48058 | 5/20 | 0.76 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.76 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.76 |
| ▸ | GRIK5 | Q16478 | 5/20 | 0.76 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.76 |
| ▸ | GRIK4 | Q16099 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zonampanel SCHEMBL29379917 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| Zonampanel SCHEMBL3045139 | 0.99 | SLC22A6 (0.98) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8192737 | 0.96 | SLC22A6 (0.92) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL7814578 | 0.91 | SLC22A6 (0.84) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8189664 | 0.90 | SLC22A6 (0.82) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8189677 | 0.89 | SLC22A6 (0.79) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL30661074 | 0.89 | SLC22A6 (0.79) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8191566 | 0.88 | SLC22A6 (0.78) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL7811014 | 0.87 | SLC22A6 (0.77) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 | |
| SCHEMBL8191240 | 0.87 | SLC22A6 (0.77) | SLC22A6SLC22A8GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750024-B2 | Remedy for glioblastoma | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | claimed |
| US-20050234063-A1 | Therapeutic agent for brain hemorrhage | ASTELLAS PHARMA INC. (JP) | 2005-10-20 | — | — | US | claimed |
| US-20050165009-A1 | Remedy for glioblastoma | ASTELLAS PHARMA INC. (JP) | 2005-07-28 | — | — | US | claimed |
| US-20050130978-A1 | Novel crystal of quinoxalinedione derivative anhydride | ASTELLAS PHARMA INC. (JP) | 2005-06-16 | — | — | US | claimed |
| EP-1518556-A1 | THERAPEUTIC AGENT FOR BRAIN HEMORRHAGE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | claimed |
| EP-1496057-A1 | NOVEL CRYSTAL OF QUINOXALINEDIONE DERIVATIVE ANHYDRIDE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-01-12 | — | — | EP | claimed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | claimed |
| US-20030144295-A1 | A synergistic antiischemic mixture of a tissue plasminogen activator, e.g. alteplase, pamiteplase, and zonampanel(7-imidazol-1-yl-6-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -1-yl acetic acid for strokes or cerebral infarctions | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2003-07-31 | — | — | US | claimed |
| EP-1316313-A2 | Composition for the treatment of ischemic stroke containing zonampanel and a tissue plasminogen activator | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-06-04 | — | — | EP | claimed |
| EP-0784054-B1 | 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVES AND USE AS GLUTAMATE RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMA CO LTD (JP) | 2001-11-28 | — | — | EP | claimed |
| US-6096743-A | 1,2,3,4-tetrahydroquinoxalinedione derivative | YAMANOUCHI PHARMACEUTICALS CO., LTD. (JP) | 2000-08-01 | — | — | US | claimed |
| EP-0784054-A1 | 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-07-16 | — | — | EP | claimed |
| WO-2023042888-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023042887-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE, EXCESS WEIGHT, OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| EP-2468732-B1 | 1H-Quinazoline-2,4-diones | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | disclosed |
| JP-2000281676-A | NEW PRODUCTION METHOD OF AMPA ANTAGONISTIC COMPOUND | YAMANOUCHI PHARMACEUT CO LTD | 2000-10-10 | — | — | JP | disclosed |
| US-6096743-A | 1,2,3,4-tetrahydroquinoxalinedione derivative | YAMANOUCHI PHARMACEUTICALS CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| CN-1168670-A | 1,2,3,4-tetrahydroquinoxalindione derivative | YAMANOUCHI PHARMA CO LTD (JP) | 1997-12-24 | — | — | CN | disclosed |
| EP-0784054-A1 | 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | LTB4R2, LTB4R, LTC4S | GRIA1 2085/4885GRIA2 2341/4885GRIA3 2201/4885 |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | GRIA1 115/4885GRIA2 201/4885GRIA3 143/4885 |
| US-20050165009-A1 | Remedy for glioblastoma | GRM2, GRM1, GRM3 | GRIA1 17/4885GRIA2 19/4885GRIA3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.